Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension

Circulation

Volumn 102, Issue 8, 2000, Pages 865-870

  Nagaya, Noritoshi ^a   Nishikimi, Toshio ^a   Uematsu, Masaaki ^a   Satoh, Toru ^a   Kyotani, Shingo ^a   Sakamaki, Fumio ^a   Kakishita, Mikio ^a   Fukushima, Kengo ^a   Okano, Yoshiaki ^a   Nakanishi, Norifumi ^a   Miyatake, Kunio ^a   Kangawa, Kenji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Hypertension, pulmonary; Mortality; Natriuretic peptides

Indexed keywords

ADRENALIN; ANTICOAGULANT AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CATECHOLAMINE; DIGITALIS; DIURETIC AGENT; NITRATE; NORADRENALIN; PROSTACYCLIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SURVIVAL RATE;

EID: 0034702908     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.8.865     Document Type: Article

References (23)

1. Primary pulmonary hypertension: A national prospective study
2. Primary pulmonary hypertension
3. Survival in patients With primary pulmonary hypertension: Results from a national prospective registry
4. Prostacyclin (epoprostenol), and heart-lung transplantation as treatments for severe pulmonary hypertension
5. Survival in primary pulmonary hypertension: Validation of a prognostic equation
6. A new natriuretic peptide in porcine brain
7. Brain natriuretic peptide (BNP) as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, ANP and BNP
8. Localization and mechanism of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
9. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide
10. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
11. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension
12. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)
13. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): Results of a randomized trial
14. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
15. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
16. Orally active prostacyclin analogue in primary pulmonary hypertension
17. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
18. Renal, hemodynamic and hormonal interactions between atrial natriuretic factor and arginine vasopressin in patients with congestive heart failure
19. Standardized intracardiac measurements of 2-dimensional echocardiography
20. Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide
21. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction
22. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels
23. Effect of hemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure